Portola rolls out $115M IPO plan as more biotech outfits go public

Ryan McBride The list of biotechs going public grows longer. With public investors warming to biotech IPOs, Portola Pharmaceuticals has proposed a public debut with a relatively sizable ...

Valeant, Actavis team up on two more authorized generics

Tracy Staton Valeant Pharmaceuticals ($ VRX) and Actavis ($ ACT) are getting downright buddy-buddy. Less than a week after partnering up on three skin products, the two companies ...
Page 8 of 8« First...45678
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS